In genetics , a regulator gene , regulator , or regulatory gene is a gene involved in controlling the expression of one or more other genes. Regulatory sequences , which encode regulatory genes, are often at the five prime end (5') to the start site of transcription of the gene they regulate. In addition, these sequences can also be found at the three prime end (3') to the transcription start site. In both cases, whether the regulatory sequence occurs before (5') or after (3') the gene it regulates, the sequence is often many kilobases away from the transcription start site . A regulator gene may encode a protein , or it may work at the level of RNA , as in the case of genes encoding microRNAs . An example of a regulator gene is a gene that codes for a repressor protein that inhibits the activity of an operator (a gene which binds repressor proteins thus inhibiting the translation of RNA to protein via RNA polymerase ).
43-448: Myc is a family of regulator genes and proto-oncogenes that code for transcription factors . The Myc family consists of three related human genes: c-myc ( MYC ), l-myc ( MYCL ), and n-myc ( MYCN ). c-myc (also sometimes referred to as MYC ) was the first gene to be discovered in this family, due to homology with the viral gene v-myc . In cancer , c-myc is often constitutively (persistently) expressed. This leads to
86-452: A "Haplo-insufficient" genotype noted as Myc+/-. The phenotypes seen oppose the effects of normal aging and are shared with many other long-lived mouse models such as CR (calorie restriction) ames dwarf, rapamycin, metformin and resveratrol. One study found that Myc and p53 genes were key to the survival of chronic myeloid leukaemia (CML) cells. Targeting Myc and p53 proteins with drugs gave positive results on mice with CML. Myc genes play
129-444: A 'stem-like' state alongside transcription factors Oct4 , Sox2 and Klf4 . It has since been shown that it is possible to generate iPSCs without c-Myc . Myc has been shown to interact with: Regulator gene In prokaryotes , regulator genes often code for repressor proteins . Repressor proteins bind to operators or promoters , preventing RNA polymerase from transcribing RNA. They are usually constantly expressed so
172-423: A crucial role in drug resistance . Circumvention of such actors is a challenge in cancer therapy . Negative regulators of cell death in cancer include cFLIP , Bcl 2 family , Survivin , HSP , IAP , NF-κB , Akt , mTOR , and FADD . There are several different techniques to detect regulatory genes, but of the many there are a certain few that are used more frequently than others. One of these select few
215-399: A nearby gene. In prokaryotes, a well-known activator protein is the catabolite activator protein (CAP), involved in positive control of the lac operon . In the regulation of gene expression , studied in evolutionary developmental biology (evo-devo), both activators and repressors play important roles. Regulatory genes can also be described as positive or negative regulators, based on
258-553: A number of normal roles in stem cells including pluripotent stem cells. In neural stem cells, N-Myc promotes a rapidly proliferative stem cell and precursor-like state in the developing brain, while inhibiting differentiation. In hematopoietic stem cells, Myc controls the balance between self-renewal and differentiation. In particular, long-term hematopoietic stem cells (LT-HSCs) express low levels of c-Myc, ensuring self-renewal. Enforced expression of c-Myc in LT-HSCs promotes differentiation at
301-431: A promising target for anti-cancer drugs. Unfortunately, Myc possesses several features that have rendered it difficult to drug to date, such that any anti-cancer drugs aimed at inhibiting Myc may continue to require perturbing the protein indirectly, such as by targeting the mRNA for the protein rather than via a small molecule that targets the protein itself. c-Myc also plays an important role in stem cell biology and
344-440: A role in the development of some prostate cancers , and could help predict whether these tumors will increase in size or spread to other parts of the body. In cancer cells, EP300 mutations prevent the gene from producing any functional protein. Without p300, cells cannot effectively restrain growth and division, which can allow cancerous tumors to form. EP300 has been shown to interact with: This article incorporates text from
387-451: A sequence spanning both transactivation domains 9aaTADs of transcription factor p53. Mutations in the EP300 gene are responsible for a small percentage of cases of Rubinstein-Taybi syndrome . These mutations result in the loss of one copy of the gene in each cell, which reduces the amount of p300 protein by half. Some mutations lead to the production of a very short, nonfunctional version of
430-549: A viable animal with small body size. Drosophila has subsequently been used to implicate Myc in cell competition, endoreplication, and cell growth. During the discovery of Myc gene, it was realized that chromosomes that reciprocally translocate to chromosome 8 contained immunoglobulin genes at the break-point. To study the mechanism of tumorigenesis in Burkitt lymphoma by mimicking expression pattern of Myc in these cancer cells, transgenic mouse models were developed. Myc gene placed under
473-519: Is B cell proliferation, and gain of MYC has been associated with B cell malignancies and their increased aggressiveness, including histological transformation. In B cells, Myc acts as a classical oncogene by regulating a number of pro-proliferative and anti-apoptotic pathways, this also includes tuning of BCR signaling and CD40 signaling in regulation of microRNAs (miR-29, miR-150, miR-17-92). c-Myc induces MTDH (AEG-1) gene expression and in turn itself requires AEG-1 oncogene for its expression. Myc-nick
SECTION 10
#1732854640356516-480: Is a cytoplasmic form of Myc produced by a partial proteolytic cleavage of full-length c-Myc and N-Myc. Myc cleavage is mediated by the calpain family of calcium-dependent cytosolic proteases. The cleavage of Myc by calpains is a constitutive process but is enhanced under conditions that require rapid downregulation of Myc levels, such as during terminal differentiation. Upon cleavage, the C-terminus of Myc (containing
559-411: Is a technique that utilizes multiple sequence alignments to determine locations of conserved sequences such as regulatory elements. Along with multiple sequence alignments, phylogenetic footprinting also requires statistical rates of conserved and non-conserved sequences. Using the information provided by multiple sequence alignments and statistical rates, one can identify the best conserved motifs in
602-834: Is activated upon various mitogenic signals such as serum stimulation or by Wnt , Shh and EGF (via the MAPK/ERK pathway ). By modifying the expression of its target genes, Myc activation results in numerous biological effects. The first to be discovered was its capability to drive cell proliferation (upregulates cyclins, downregulates p21), but it also plays a very important role in regulating cell growth (upregulates ribosomal RNA and proteins), apoptosis (downregulates Bcl-2 ), differentiation, and stem cell self-renewal. Nucleotide metabolism genes are upregulated by Myc, which are necessary for Myc induced proliferation or cell growth. There have been several studies that have clearly indicated Myc's role in cell competition. A major effect of c-myc
645-451: Is an enzyme that, in humans, is encoded by the EP300 gene . It functions as histone acetyltransferase that regulates transcription of genes via chromatin remodeling by allowing histone proteins to wrap DNA less tightly. This enzyme plays an essential role in regulating cell growth and division , prompting cells to mature and assume specialized functions (differentiate), and preventing
688-517: Is called ChIP-chip. ChIP-chip is an in vivo technique used to determine genomic binding sites for transcription factors in two component system response regulators. In vitro microarray based assay (DAP-chip) can be used to determine gene targets and functions of two component signal transduction systems. This assay takes advantage of the fact that response regulators can be phosphorylated and thus activated in vitro using small molecule donors like acetyl phosphate . Phylogenetic footprinting
731-436: Is controlled by a wide variety of noncoding RNAs, including miRNA , lncRNA , and circRNA . Some of these RNAs have been shown to be specific for certain types of human tissues and tumors. Changes in the expression of such RNAs can potentially be used to develop targeted tumor therapy. In Drosophila Myc is encoded by the diminutive locus, (which was known to geneticists prior to 1935). Classical diminutive alleles resulted in
774-589: Is important in the processes of cell proliferation and differentiation. It mediates cAMP -gene regulation by binding specifically to phosphorylated CREB protein. p300 HAT contains a bromodomain which is involved in IL6 signaling. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and, thus, plays a role in the stimulation of hypoxia-induced genes such as VEGF . The p300 protein carries out its function of activating transcription by binding to transcription factors , and
817-668: Is its implication in Burkitt's lymphoma . In Burkitt's lymphoma, cancer cells show chromosomal translocations , most commonly between chromosome 8 and chromosome 14 [t(8;14)]. This causes c-Myc to be placed downstream of the highly active immunoglobulin (Ig) promoter region, leading to overexpression of Myc . The protein products of Myc family genes all belong to the Myc family of transcription factors, which contain bHLH (basic helix-loop-helix) and LZ ( leucine zipper ) structural motifs. The bHLH motif allows Myc proteins to bind with DNA , while
860-616: Is that these regulatory elements get activated by the binding of transcription factors , proteins that bind to specific DNA sequences, and control mRNA transcription. There could be several transcription factors that need to bind to one regulatory element in order to activate it. In addition, several other proteins, called transcription cofactors, bind to the transcription factors themselves to control transcription. Negative regulators act to prevent transcription or translation. Examples such as cFLIP suppress cell death mechanisms leading to pathological disorders like cancer , and thus play
903-474: Is thought to function by upregulating transcript elongation of actively transcribed genes through the recruitment of transcriptional elongation factors. It can also act as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator , it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. This activity could contribute to DNA amplification in cancer cells. Myc
SECTION 20
#1732854640356946-524: The DNA binding domain ) is degraded, while Myc-nick, the N-terminal segment 298-residue segment remains in the cytoplasm . Myc-nick contains binding domains for histone acetyltransferases and for ubiquitin ligases . The functions of Myc-nick are currently under investigation, but this new Myc family member was found to regulate cell morphology, at least in part, by interacting with acetyl transferases to promote
989-529: The orthologous regions of interest. EP300 1L3E , 1P4Q , 2K8F , 2MH0 , 2MZD , 3BIY , 3I3J , 3IO2 , 3P57 , 3T92 , 4BHW , 4PZR , 4PZS , 4PZT , 5BT3 2033 328572 ENSG00000100393 ENSMUSG00000055024 Q09472 B2RWS6 NM_001429 NM_001362843 NM_177821 NP_001420 NP_001349772 NP_808489 Histone acetyltransferase p300 also known as p300 HAT or E1A-associated protein p300 (where E1A = adenovirus early region 1A ) also known as EP300 or p300
1032-693: The MYC gene was found in a significant number of epithelial ovarian cancer cases. In TCGA datasets, the amplification of Myc occurs in several cancer types, including breast, colorectal, pancreatic, gastric, and uterine cancers. In the experimental transformation process of normal cells into cancer cells, the MYC gene can cooperate with the RAS gene. Expression of Myc is highly dependent on BRD4 function in some cancers. BET inhibitors have been used to successfully block Myc function in pre-clinical cancer models and are currently being evaluated in clinical trials. MYC expression
1075-423: The absence of Myc are strongly boosted in the presence of Myc, whereas genes for which expression is low in the absence Myc get only a small boost when Myc is present. Inactivation of SUMO-activating enzyme ( SAE1 / SAE2 ) in the presence of Myc hyperactivation results in mitotic catastrophe and cell death in cancer cells. Hence inhibitors of SUMOylation may be a possible treatment for cancer. Amplification of
1118-433: The acetylation of α-tubulin . Ectopic expression of Myc-nick accelerates the differentiation of committed myoblasts into muscle cells. A large body of evidence shows that Myc genes and proteins are highly relevant for treating tumors. Except for early response genes, Myc universally upregulates gene expression. Furthermore, the upregulation is nonlinear. Genes for which expression is already significantly upregulated in
1161-492: The cell always has a supply of repressor molecules on hand. Inducers cause repressor proteins to change shape or otherwise become unable to bind DNA, allowing RNA polymerase to continue transcription. Regulator genes can be located within an operon , adjacent to it, or far away from it. Other regulatory genes code for activator proteins . An activator binds to a site on the DNA molecule and causes an increase in transcription of
1204-411: The control of IgM heavy chain enhancer in transgenic mice gives rise to mainly lymphomas. Later on, in order to study effects of Myc in other types of cancer, transgenic mice that overexpress Myc in different tissues (liver, breast) were also made. In all these mouse models overexpression of Myc causes tumorigenesis, illustrating the potency of Myc oncogene. In a study with mice, reduced expression of Myc
1247-505: The development of AML following chemotherapy for other forms of cancer. Mutations in the EP300 gene have been identified in several other types of cancer. These mutations are somatic, which means they are acquired during a person's lifetime and are present only in certain cells. Somatic mutations in the EP300 gene have been found in a small number of solid tumors, including cancers of the colon and rectum , stomach , breast , and pancreas . Studies suggest that EP300 mutations may also play
1290-498: The environmental conditions that surround the cell. Positive regulators are regulatory elements that permit RNA polymerase binding to the promoter region, thus allowing transcription to occur. In terms of the lac operon, the positive regulator would be the CRP-cAMP complex that must be bound close to the site of the start of transcription of the lac genes. The binding of this positive regulator allows RNA polymerase to bind successfully to
1333-427: The expense of self-renewal, resulting in stem cell exhaustion. In pathological states and specifically in acute myeloid leukemia, oxidant stress can trigger higher levels of Myc expression that affects the behavior of leukemia stem cells. c-Myc plays a major role in the generation of induced pluripotent stem cells (iPSCs). It is one of the original factors discovered by Yamanaka et al. to encourage cells to return to
Myc - Misplaced Pages Continue
1376-540: The growth of cancerous tumors. The p300 protein appears to be critical for normal development before and after birth . The EP300 gene is located on the long (q) arm of the human chromosome 22 at position 13.2. This gene encodes the adenovirus E1A -associated cellular p300 transcriptional co-activator protein. EP300 is closely related to another gene, CREB binding protein , which is found on human chromosome 16 . p300 HAT functions as histone acetyltransferase that regulates transcription via chromatin remodeling, and
1419-399: The increased expression of many genes, some of which are involved in cell proliferation , contributing to the formation of cancer. A common human translocation involving c-myc is critical to the development of most cases of Burkitt lymphoma . Constitutive upregulation of Myc genes have also been observed in carcinoma of the cervix, colon, breast, lung and stomach. Myc is thus viewed as
1462-421: The lac repressor to RNA polymerase's binding site inhibits the transcription of the lac genes. Only when an inducer is bound to the lac repressor will the binding site be free for RNA polymerase to carry out transcription of the lac genes. Promoters reside at the beginning of the gene and serve as the site where the transcription machinery assembles and transcription of the gene begins. Enhancers turn on
1505-550: The leucine zipper TF-binding motif allows dimerization with Max , another bHLH transcription factor. Myc mRNA contains an IRES (internal ribosome entry site) that allows the RNA to be translated into protein when 5' cap -dependent translation is inhibited, such as during viral infection. Myc proteins are transcription factors that activate expression of many pro-proliferative genes through binding enhancer box sequences ( E-boxes ) and recruiting histone acetyltransferases (HATs). Myc
1548-485: The p300 protein, while others prevent one copy of the gene from making any protein at all. Although researchers do not know how a reduction in the amount of p300 protein leads to the specific features of Rubinstein-Taybi syndrome, it is clear that the loss of one copy of the EP300 gene disrupts normal development. Chromosomal rearrangements involving chromosome 22 have rarely been associated with certain types of cancer . These rearrangements, called translocations , disrupt
1591-431: The promoter of the lac gene sequence which advances the transcription of lac genes ; lac Z, lac Y, and lac A. Negative regulators are regulatory elements which obstruct the binding of RNA polymerase to the promoter region, thus repressing transcription. In terms of the lac operon, the negative regulator would be the lac repressor which binds to the promoter in the same site that RNA polymerase normally binds. The binding of
1634-411: The promoters at specific locations, times, and levels and can be simply defined as the “promoters of the promoter.” Silencers are thought to turn off gene expression at specific time points and locations. Insulators, also called boundary elements, are DNA sequences that create cis-regulatory boundaries that prevent the regulatory elements of one gene from affecting neighboring genes. The general dogma
1677-403: The region of chromosome 22 that contains the EP300 gene. For example, researchers have found a translocation between chromosomes 8 and 22 in several people with a cancer of blood cells called acute myeloid leukemia (AML). Another translocation, involving chromosomes 11 and 22, has been found in a small number of people who have undergone cancer treatment. This chromosomal change is associated with
1720-538: The transcription machinery. On the basis of this function, p300 is called a transcriptional coactivator . The p300 interaction with transcription factors is managed by one or more of p300 domains: the nuclear receptor interaction domain (RID), the KIX domain ( CREB and MYB interaction domain), the cysteine / histidine regions (TAZ1/CH1 and TAZ2/CH3) and the interferon response binding domain (IBiD). The last four domains, KIX, TAZ1, TAZ2 and IBiD of p300, each bind tightly to
1763-463: Was first established after discovery of homology between an oncogene carried by the Avian v irus, My elo c ytomatosis ( v-myc ; P10395 ) and a human gene over-expressed in various cancers, c ellular Myc ( c-Myc ). Later, discovery of further homologous genes in humans led to the addition of n-Myc and l-Myc to the family of genes. The most frequently discussed example of c-Myc as a proto-oncogene
Myc - Misplaced Pages Continue
1806-511: Was one of the original Yamanaka factors used to reprogram somatic cells into induced pluripotent stem cells . In the human genome , C-myc is located on chromosome 8 and is believed to regulate expression of 15% of all genes through binding on enhancer box sequences ( E-boxes ). In addition to its role as a classical transcription factor, N-myc may recruit histone acetyltransferases (HATs). This allows it to regulate global chromatin structure via histone acetylation. The Myc family
1849-500: Was shown to induce longevity, with significantly extended median and maximum lifespans in both sexes and a reduced mortality rate across all ages, better health, cancer progression was slower, better metabolism and they had smaller bodies. Also, Less TOR, AKT, S6K and other changes in energy and metabolic pathways (such as AMPK, more oxygen consumption, more body movements, etc.). The study by John M. Sedivy and others used Cre-Loxp -recombinase to knockout one copy of Myc and this resulted in
#355644